Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R1XF
|
|||
| Former ID |
DIB002356
|
|||
| Drug Name |
212Pb-TCMC-trastuzumab
|
|||
| Synonyms |
Lead212-labeled trastuzumab (cancer), AREVA/NCI; Radioimmunotherapeutic-212Pb (cancer), AREVA/NCI; Radioimmunotherapeutic-lead212 (cancer), AREVA/NCI
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
National Cancer Institute
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01384253) Safety Study of b-TCMC-Trastuzumab Radio Immunotherapy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.